This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Naltrexone Implants as Relapse Prevention

This study has been terminated.
(Recruitment difficulties. Reframed as pilot study)
Information provided by:
University of Oslo Identifier:
First received: December 22, 2005
Last updated: December 10, 2013
Last verified: December 2005

The purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. Participants in the naltrexone experimental group are prematched in a pairwise fashion with other patients who do not want a naltrexone implant during the first six months after ending inpatient treatment, but who reiceive treatment as usual (TAU) from the Norwegian healthcare system.

The hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up.

We also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.

Condition Intervention Phase
Opioid Dependency Drug: Implantation of naltrexone implants Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.

Resource links provided by NLM:

Further study details as provided by University of Oslo:

Primary Outcome Measures:
  • Primary Outcomes: drug use at 6(12/18)months by self report, hair analysis; days in work or education, number of drug-free friends at 6 (12/18)months by self report

Secondary Outcome Measures:
  • Secondary Outcomes: depression at 6(12/18)months by BDI and Hopkins SCL-25; quality of life at 6(12/18)months by EuropASI

Enrollment: 12
Study Start Date: May 2005
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • soon to complete inpatient treatment for opioid addiction
  • living in southern Norway

Exclusion Criteria:

  • psychosis / major depression, currently not treated
  • pregnancy
  • liver enzymes: ASAT or ALAT > threefold above upper boundary
  • maintenance treatment with methadone or buprenorphine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00269607

Sponsors and Collaborators
University of Oslo
Study Director: Helge Waal, professor Unit for addiction medicine, Institute of psychiatry, University of Oslo
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Oslo, Institute of Psychiatry, Professor Edvard Hauff, Institute of Psychiatry, University of Oslo Identifier: NCT00269607     History of Changes
Other Study ID Numbers: 11899
Study First Received: December 22, 2005
Last Updated: December 10, 2013

Keywords provided by University of Oslo:
Substance abuse
Relapse prevention
opioid antagonist

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 21, 2017